Design and created by Guideline Central in participation with the International Society on Thrombosis and Haemostasis.
International Society on Thrombosis and Haemostasis
Publication Date: Jun 17, 2025
Page Last Updated: May 5, 2026
| Grade | Quality of Evidence |
|---|---|
| High | We are very confident that the true effect lies close to the estimate of the effect. |
| Moderate | We are moderately confident that the true effect lies close to that of the estimate of the effect. There is a possibility that it is substantially different. |
| Low | Our confidence that the true effect lies close to that of the estimate of the effect is low. The true effect may be substantially different from the estimate of the effect. |
| Very low | We have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. |
| Evidence / Knowledge Gap | Available evidence insufficient to determine true effect. |
| Grade | Strength of Recommendation | ||
|---|---|---|---|
| Strong “AGA recommends...” | For the Patient | For the Clinician | For policy makers |
| Most individuals in this situation would want the recommended course and only a small proportion would not. | Most individuals should receive the intervention. Formal decision aids are not likely to be needed to help individuals make decisions consistent with their values and preferences. | The recommendation can be adapted as policy or performance measure in most situations. | |
| Conditional (weak) “AGA suggests...” | The majority of individuals in this situation would want the suggested course, but many would not. | Different choices will be appropriate for individual patients consistent with his or her values and preferences. Use shared decision making. Decision aids may be useful in helping patients make decisions consistent with their individual risks, values, and preferences. | Policy making will require substantial debate and involvement of various stakeholders. Performance measures should assess whether decision making is appropriate. |
| No recommendation “AGA makes no recommendation...” | The confidence in the effect estimate is so low that any effect estimate is speculative at this time. | ||
Zheng XL, Al-Housni Z, Cataland SR, Coppo P, Geldziler B, Germini F, Iorio A, Keepanasseri A, Masias C, Matsumoto M, McCrae KR, McIntyre J, Mustafa RA, Peyvandi F, Russell L, Tarawneh R, Vesely SK; International Society on Thrombosis and Haemostasis. 2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2025 Jun 17:S1538-7836(25)00360-5. doi: 10.1016/j.jtha.2025.06.002. Epub ahead of print. PMID: 40533296.
The evidence-based guidelines of the International Society on Thrombosisand Haemostasis (ISTH) are intended to support patients, clinicians, and other healthcare professionals in their decisions about the initial diagnosis and management ofacute Thrombotic thrombocytopenic purpura (TTP).
D003933 - Diagnosis
D011697 - Purpura, Thrombotic Thrombocytopenic
D003933 - Diagnosis
D011697 - Purpura, Thrombotic Thrombocytopenic
Guideline Central and select third party use “cookies” on this website to enhance the user experience.
This technology helps us gather statistical and analytical information to optimize the relevant content for you.
The user also has the option to opt-out which may have an effect on the browsing experience.